High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study
Modern Rheumatology · 2026
DOI: 10.1093/mr/roaf095 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Ayaka Maeda und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Glucocorticoids, Immunosuppressive Agents, Hereditary Autoinflammatory Diseases, Genetic Diseases, X-Linked. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI Grants-in-Aid for Scientific Research (C), Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Objectives
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disease caused by somatic variants of the UBA1 gene. Due to uncertainty around treatment strategies and limited therapeutic options, this study aimed to characterise the clinical treatment and outcomes of VEXAS syndrome patients in Japan.
Methods
We retrospectively analysed data on clinical manifestations, treatments, and outcomes from 46 male patients diagnosed with VEXAS syndrome. Twelve patients at our institution were evaluated for remission using the French VEXAS group criteria.
Results
All patients (median age at onset: 71.4 years) received systemic glucocorticoid therapy (mean maximum dose: 47.4 mg/day; mean minimum dose: 8.5 mg/day). Most patients required continuous glucocorticoid treatment of ≥10 mg/day, and tapering was generally difficult. Among the patients followed at our institution, only 42% (5/12) achieved complete remission at least once during follow-up. Tocilizumab was the most frequently administered immunosuppressant (n = 24, 52.2%); Janus kinase inhibitors and azacitidine, reported to be effective overseas, were prescribed in only three and two cases, respectively.
Conclusions
This study highlights the difficulty of treating patients with VEXAS syndrome in Japan. The development of more effective treatments is urgently needed to reduce glucocorticoid dependence and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Rare Disease Genomics, Yokohama City University Hospital, Yokohama, Japan.
- Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Department of General Internal Medicine, Chutoen General Medical Center, Kakegawa, Japan.
ORCID-Profile: Ayaka Maeda, Yohei Kirino, Naomi Tsuchida, Yuri Uchiyama, Daisuke Kobayashi, Tomoyuki Asano, Yuji Ito, Kosuke Katsuo, Ayaka Kato, Ichiro Mori, Hiroyuki Yamaguchi, Toshimasa Shimizu, Mitsumasa Kishimoto, Nobuhiro Oda, Ken Nagahata, Hiroshi Kobayashi, Yoichi Takeuchi, Hiroyuki Hagiyama, Kaori Uchino, Yuji Miyoshi, Hiroaki Ida, Kaori Kashino, Yusuke Yoshida, Hidenori Ohnishi, Noriyuki Takahashi, Yuichiro Fujieda, Nobuyuki Horita, Kaoru Takase-Minegishi, Naomichi Matsumoto, Hideaki Nakajima
Förderung
- Japan Society for the Promotion of Science KAKENHI Grants-in-Aid for Scientific Research (C)
- Japan Agency for Medical Research and Development
Zitieren
APA
Maeda, A., Kirino, Y., Tsuchida, N., Uchiyama, Y., Kobayashi, D., Asano, T., Ito, Y., Katsuo, K., Kato, A., Mori, I., Yamaguchi, H., Shimizu, T., Kobayashi, S., Kishimoto, M., Oda, N., Rokutanda, R., Nagahata, K., Fujiwara, H., Kobayashi, H., …, & Nakajima, H. (2026). High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf095
Vancouver
Maeda A, Kirino Y, Tsuchida N, Uchiyama Y, Kobayashi D, Asano T, et al. High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study. Modern Rheumatology. 2026. doi:10.1093/mr/roaf095
BibTeX
@article{Maeda2026,
author = {Maeda, Ayaka and Kirino, Yohei and Tsuchida, Naomi and Uchiyama, Yuri and Kobayashi, Daisuke and Asano, Tomoyuki and Ito, Yuji and Katsuo, Kosuke and Kato, Ayaka and Mori, Ichiro and Yamaguchi, Hiroyuki and Shimizu, Toshimasa and Kobayashi, Satoshi and Kishimoto, Mitsumasa and Oda, Nobuhiro and Rokutanda, Ryo and Nagahata, Ken and Fujiwara, Hiroshi and Kobayashi, Hiroshi and Takeuchi, Yoichi and Hagiyama, Hiroyuki and Umeda, Naoki and Uchino, Kaori and Miyoshi, Yuji and Hidaka, Yukiko and Ida, Hiroaki and Akasaka, Keiichi and Kashino, Kaori and Yoshida, Yusuke and Ohnishi, Hidenori and Takahashi, Noriyuki and Fujieda, Yuichiro and Horita, Nobuyuki and Takase-Minegishi, Kaoru and Matsumoto, Naomichi and Nakajima, Hideaki},
title = {High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roaf095}
}
EUVIMED